We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed the most recent trading day at $241.94, moving -0.37% from the previous trading session. This change lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow lost 0.1%, while the tech-heavy Nasdaq added 0.05%.
Prior to today's trading, shares of the world's largest biotech drugmaker had gained 8.17% over the past month. This has outpaced the Medical sector's gain of 5.44% and the S&P 500's gain of 2.48% in that time.
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date. In that report, analysts expect AMGN to post earnings of $3.43 per share. This would mark year-over-year growth of 0.29%. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, down 3.95% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $14.57 per share and revenue of $23.15 billion, which would represent changes of +1.18% and -2.5%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for AMGN. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.04% higher. AMGN is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, AMGN is holding a Forward P/E ratio of 16.67. For comparison, its industry has an average Forward P/E of 24.92, which means AMGN is trading at a discount to the group.
We can also see that AMGN currently has a PEG ratio of 2.31. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. AMGN's industry had an average PEG ratio of 1.76 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
Amgen (AMGN - Free Report) closed the most recent trading day at $241.94, moving -0.37% from the previous trading session. This change lagged the S&P 500's daily loss of 0.04%. Elsewhere, the Dow lost 0.1%, while the tech-heavy Nasdaq added 0.05%.
Prior to today's trading, shares of the world's largest biotech drugmaker had gained 8.17% over the past month. This has outpaced the Medical sector's gain of 5.44% and the S&P 500's gain of 2.48% in that time.
Wall Street will be looking for positivity from AMGN as it approaches its next earnings report date. In that report, analysts expect AMGN to post earnings of $3.43 per share. This would mark year-over-year growth of 0.29%. Our most recent consensus estimate is calling for quarterly revenue of $5.98 billion, down 3.95% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $14.57 per share and revenue of $23.15 billion, which would represent changes of +1.18% and -2.5%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for AMGN. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.04% higher. AMGN is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, AMGN is holding a Forward P/E ratio of 16.67. For comparison, its industry has an average Forward P/E of 24.92, which means AMGN is trading at a discount to the group.
We can also see that AMGN currently has a PEG ratio of 2.31. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. AMGN's industry had an average PEG ratio of 1.76 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.